Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) Inventory-to-Revenue : 0.34 (As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Clinuvel Pharmaceuticals Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Clinuvel Pharmaceuticals's Average Total Inventories for the quarter that ended in Dec. 2023 was $7.40 Mil. Clinuvel Pharmaceuticals's Revenue for the six months ended in Dec. 2023 was $21.59 Mil. Clinuvel Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.34.

Clinuvel Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Dec. 2023 increased from Jun. 2023 (0.14) to Jun. 2023 (0.34)

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Clinuvel Pharmaceuticals's Days Inventory for the six months ended in Dec. 2023 was 1,880.41.

Inventory Turnover measures how fast the company turns over its inventory within a year. Clinuvel Pharmaceuticals's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.10.

Clinuvel Pharmaceuticals Inventory-to-Revenue Historical Data

The historical data trend for Clinuvel Pharmaceuticals's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clinuvel Pharmaceuticals Inventory-to-Revenue Chart

Clinuvel Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Inventory-to-Revenue

Get a 7-Day Free Trial

0.05

0.04

0.07

Clinuvel Pharmaceuticals Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Inventory-to-Revenue	Get a 7-Day Free Trial															0.13	0.06	0.11	0.14	0.34

Competitive Comparison of Clinuvel Pharmaceuticals's Inventory-to-Revenue

For the Biotechnology subindustry, Clinuvel Pharmaceuticals's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clinuvel Pharmaceuticals's Inventory-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where Clinuvel Pharmaceuticals's Inventory-to-Revenue falls into.

Clinuvel Pharmaceuticals Inventory-to-Revenue Calculation

Clinuvel Pharmaceuticals's Inventory-to-Revenue for the fiscal year that ended in Jun. 2023 is calculated as

	Inventory-to-Revenue (A: Jun. 2023 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (A: Jun. 2022 )	+	Total Inventories (A: Jun. 2023 ))	/	count )	/	Revenue (A: Jun. 2023 )
=	( (1.287	+	6.389)	/	2 )	/	52.564
=	3.838					/	52.564
=	0.07

Clinuvel Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

	Inventory-to-Revenue (Q: Dec. 2023 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (Q: Jun. 2023 )	+	Total Inventories (Q: Dec. 2023 ))	/	count )	/	Revenue (Q: Dec. 2023 )
=	( (6.389	+	8.407)	/	2 )	/	21.591
=	7.398					/	21.591
=	0.34

Clinuvel Pharmaceuticals (OTCPK:CLVLF) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Clinuvel Pharmaceuticals's Days Inventory for the six months ended in Dec. 2023 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Dec. 2023 )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
	=	7.398	/	0.718	*	365 / 2
	=	1,880.41

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Clinuvel Pharmaceuticals's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Dec. 2023 )	/	Average Total Inventories (Q: Dec. 2023 )
	=	0.718	/	7.398
	=	0.10

Clinuvel Pharmaceuticals Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of Clinuvel Pharmaceuticals's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clinuvel Pharmaceuticals Ltd (OTCPK:CLVLF) » Definitions » Inventory-to-Revenue

Comparable Companies

Traded in Other Exchanges

CLVLY:USA UR9:Germany CUV:Australia

Address

535 Bourke Street, Level 11, Melbourne, VIC, AUS, 3000

Website

https://www.clinuvel.com

Clinuvel distributes a single-product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the U.S.